[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,926,034
  • Shares Outstanding, K 231,773
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 215 M
  • EBITDA $ 224 M
  • 60-Month Beta 0.72
  • Price/Sales 3.83
  • Price/Cash Flow 12.70
  • Price/Book 4.95

Options Overview Details

View History
  • Implied Volatility 65.11% (+10.81%)
  • Historical Volatility 62.71%
  • IV Percentile 56%
  • IV Rank 23.71%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 25) 0.99 (11.87%)
  • Put/Call Vol Ratio 0.94
  • Today's Volume 277
  • Volume Avg (30-Day) 727
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 106,392
  • Open Int (30-Day) 105,103
  • Expected Range 7.32 to 9.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 1
  • High Estimate $0.16
  • Low Estimate $0.16
  • Prior Year $0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.45 +11.54%
on 06/02/26
8.90 -6.58%
on 06/10/26
-0.07 (-0.84%)
since 05/18/26
3-Month
7.21 +15.25%
on 03/26/26
15.23 -45.42%
on 03/20/26
-6.56 (-44.12%)
since 03/18/26
52-Week
7.21 +15.25%
on 03/26/26
20.46 -59.38%
on 12/12/25
-9.82 (-54.16%)
since 06/18/25

Most Recent Stories

More News
INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August...

ADMA : 8.31 (-1.31%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , June 21, 2026 /PRNewswire/ --

ADMA : 8.31 (-1.31%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , June 19, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ...

ADMA : 8.31 (-1.31%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 19, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.31 (-1.31%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 18, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.31 (-1.31%)
ADMA Biologics, Inc. (ADMA) Class Action Lawsuit: Investors Face August 10, 2026, Deadline

Did you buy ADMA securities between August 9, 2024 and March 25, 2026?

ADMA : 8.31 (-1.31%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA

NEW YORK , June 18, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).   Such investors...

ADMA : 8.31 (-1.31%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.31 (-1.31%)
ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline

ADMA Biologics allegedly certified internal controls as effective while concealing channel stuffing and an undisclosed related party distributor operating from company headquarters....

ADMA : 8.31 (-1.31%)
ADMA INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

SAN DIEGO , June 17, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between...

ADMA : 8.31 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 8.85
2nd Resistance Point 8.74
1st Resistance Point 8.52
Last Price 8.31
1st Support Level 8.19
2nd Support Level 8.08
3rd Support Level 7.86

See More

52-Week High 20.46
Fibonacci 61.8% 15.40
Fibonacci 50% 13.83
Fibonacci 38.2% 12.27
Last Price 8.31
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.